Evidence map›Paper›PMID 39124868›Full record

ArticleMolecules (Basel, Switzerland)2024

C

Kai Yang, Cai-Bo Chen, Zhao-Wen Liu, Zhen-Lin Li, Yu Zeng, Zhao-Yang Wang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Copper-catalyzed and Y(OTf)RSC advances · 2026
    Article
  2. Review
  3. Synthesis of Oxazoles Containing CFMolecules (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kai YangCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.ORCID 0000-0002-9527-8974
Cai-Bo ChenCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Zhao-Wen LiuCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.ORCID 0009-0005-9603-5092
Zhen-Lin LiCollege of Pharmacy, Gannan Medical University, Ganzhou 341000, China.
Yu ZengSchool of Chemistry, South China Normal University, Guangzhou Key Laboratory of Analytical Chemistry for Biomedicine, GDMPA Key Laboratory for Process Control and Quality Evaluation of Chiral Pharmaceuticals, Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, Guangzhou 510006, China.
Zhao-Yang WangSchool of Chemistry, South China Normal University, Guangzhou Key Laboratory of Analytical Chemistry for Biomedicine, GDMPA Key Laboratory for Process Control and Quality Evaluation of Chiral Pharmaceuticals, Key Laboratory of Theoretical Chemistry of Environment, Ministry of Education, Guangzhou 510006, China.ORCID 0000-0002-2391-5938

Funding

This research was supported by the Guangdong Basic and Applied Basic Research Foundation (no. 2021A1515012342), Natural Science Foundation of Jiangxi Province (no. 20224BAB203010) and the Science and Technology Projects of Ganzhou (2023CYZ17866) 2021A1515012342, 20224BAB203010, 2023CYZ17866
6 · The paper itself

Abstract

As an important class of nitrogen-containing fused heterocyclic compounds, imidazo[1,2-a]pyridines often exhibit significant biological activities, such as analgesic, anticancer, antiosteoporosis, anxiolytic, etc. Using Y(OTf)

Indexed as

alkylationaza-Friedel–Crafts reactionimidazo[1,2-a]pyridinesLewis acid catalystthree-component reaction

Identifiers

PMID39124868
PMCPMC11313794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.